newsfilter
← Latest News
Business Wire·

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

FDA has assigned September 9, 2022 as the PDUFA date Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the resubmitted Biologics License Application (BLA) for ef